Cytokinetics, Incorporated
CYTK
$31.70
-$0.785-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.97% | -9.59% | -24.05% | -11.41% | -3.32% |
| Total Depreciation and Amortization | -1.33% | -62.38% | 30.04% | 29.70% | 26.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.70% | 246.53% | 56.45% | 9.48% | 12.08% |
| Change in Net Operating Assets | 79.76% | -7.05% | 567.39% | 140.53% | -34.05% |
| Cash from Operations | -1.63% | 11.44% | -5.50% | 18.47% | -5.91% |
| Capital Expenditure | -- | -1,575.32% | -218.64% | -167.09% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 241.96% | 237.89% | -160.54% | -884.15% | -80.32% |
| Cash from Investing | 224.61% | 236.18% | -161.68% | -893.33% | -80.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -209.44% | -1,212.61% | -1,233.64% | -1,257.55% | -350.24% |
| Issuance of Common Stock | -93.79% | -96.17% | 42.45% | 10,870.44% | 3,372.57% |
| Repurchase of Common Stock | 99.93% | -- | -- | -- | -75.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -95.42% | -98.59% | -93.68% | 14,895.63% | 1,546.16% |
| Foreign Exchange rate Adjustments | -1,100.00% | 1,560.00% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -404.62% | 259.80% | -561.32% | 305.15% | -80.71% |